PARD (Poniard Pharmaceuticals) Total Receivables: $0.00 Mil (As of Sep. 2011)


What is Poniard Pharmaceuticals Total Receivables?

Poniard Pharmaceuticals PARD Total Receivables is $0.00 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Total Receivables for the quarter that ended in Sep. 2011 was $0.00 Mil.

Poniard Pharmaceuticals Total Receivables Related Terms

Poniard Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Total Receivables Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Poniard Pharmaceuticals (PARD) has a Total Receivables of $0.00 Mil as of Sep. 2011. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Total Receivables too high?
Poniard Pharmaceuticals' current Total Receivables is $0.00 Mil.
How does Poniard Pharmaceuticals' Total Receivables compare to OBMP and NSPX?
Poniard Pharmaceuticals' Total Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Total Receivables of $0.00 Mil. The current Total Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Total Receivables is $0.00 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.